ZFPM2 and cancer: In the overall cohort, ZFPM2 rs4734879, SLC19 A2 rs2038024, ITGB3 rs5918 and GSR rs3779647 did not exhibit a significant impact on five-year DFS, regardless of genetic model (additive, recessive or dominant), sex (male vs. female) and cancer stage (III/IV vs. I/II or I/II/III vs. IV).